Continuum Advisory LLC Purchases 333 Shares of Eli Lilly and Company (NYSE:LLY)

Continuum Advisory LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,927 shares of the company's stock after acquiring an additional 333 shares during the quarter. Continuum Advisory LLC's holdings in Eli Lilly and Company were worth $1,591,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of LLY. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $43,000. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $48,000. Highline Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares during the last quarter. Capital A Wealth Management LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $63,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $66,000. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $1,011.79.

Eli Lilly and Company Stock Performance

LLY stock traded up $8.33 during midday trading on Tuesday, reaching $778.97. 2,773,370 shares of the company's stock traded hands, compared to its average volume of 3,666,228. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a 50-day moving average price of $780.81 and a two-hundred day moving average price of $800.36. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market capitalization of $738.26 billion, a PE ratio of 63.38, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's revenue was up 45.2% on a year-over-year basis. During the same period last year, the company posted $2.58 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.